Loading News...
Back to Dashboard

Twist Bioscience Corporation (TWST)

Real-time intraday values

Market Overview

From:
To:
TWST Intraday
No data available
SymbolTWST
IPO DateOct 31, 2018
CEODr. Emily Marine Leproust Ph.D.
Full Time Employees979
SectorHealthcare
IndustryDiagnostics & Research
CountryUnited States
ExchangeNasdaqGS
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Performance
PeriodReturn %Value Change
1 Day
+2.81%
+2.08 US$
5 Days
+9.98%
+6.91 US$
1 Month
+39.97%
+21.74 US$
6 Months
+146.14%
+45.20 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of TWST...

Key Statistics
Market Cap
4.74B
P/E Ratio
N/A
Div Yield
N/A
52W High
$80.50
52W Low
$23.30

Analyst Consensus

ConsensusStrong Buy
Bullish888.9%
Neutral111.1%
Bearish00.0%

52W Analyst Price Targets

Min Target
$36.00
Max Target
$80.00
Current$76.13
Avg Target$64.38

Analyst Recommendations

Target Price:$64.38($36.00 - $80.00)
FirmRatingTarget PriceUpside PotentialDate
Piper SandlerOverweight$85.00+11.65%6/11/2026
Leerink PartnersOutperform$70.00-8.05%5/5/2026
BarclaysOverweight$65.00-14.62%5/5/2026
GuggenheimBuy$60.00-21.19%5/5/2026
BairdOutperform$65.00-14.62%5/5/2026
BarclaysOverweight$55.00-27.76%4/14/2026
Evercore ISI GroupOutperform$56.00-26.44%4/6/2026
GuggenheimBuy$55.00-27.76%3/30/2026
Evercore ISI GroupOutperform$52.00-31.70%2/3/2026
BarclaysOverweight$50.00-34.32%2/3/2026
Community Thoughts

Share your analysis and sentiment on TWST

Join the community to share your analysis